These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30167527)

  • 21. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union.
    Heinemann L; Freckmann G; Koschinsky T
    J Diabetes Sci Technol; 2013 Mar; 7(2):542-7. PubMed ID: 23567012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments.
    Wild C; Erdös J; Zechmeister I
    BMC Cardiovasc Disord; 2014 Nov; 14():154. PubMed ID: 25366498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New scenario in the field of medical devices in the European Union: Switzerland and the United Kingdom become third countries.
    Fraga-García M; Taléns-Visconti R; Nácher-Alonso A; Díez-Sales O
    Farm Hosp; 2022 Jun; 46(4):244-250. PubMed ID: 36183222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
    Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
    Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
    Leo CP; Hentschel B; Szucs TD; Leo C
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices).
    Fraser AG; Nelissen RGHH; Kjærsgaard-Andersen P; Szymański P; Melvin T; Piscoi P;
    Eur Heart J Qual Care Clin Outcomes; 2022 May; 8(3):249-258. PubMed ID: 34448829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
    Shah RR; Roberts SA; Shah DR
    Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Drug Approvals in Europe Versus the United States: An Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA.
    Makuch RW; Shi R
    Ther Innov Regul Sci; 2014 May; 48(3):362-366. PubMed ID: 30235531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
    Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
    Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
    Demirci E; Omes-Smit G; Zwiers A
    Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices.
    Van Norman GA
    JACC Basic Transl Sci; 2016 Jun; 1(4):277-287. PubMed ID: 30167516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
    da Costa Gonçalves F; Demirci E; Zwiers A
    Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
    Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
    Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the international regulations for medical devices-USA versus Europe.
    Fink M; Akra B
    Injury; 2023 Oct; 54 Suppl 5():110908. PubMed ID: 37365092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.